Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy
Department of Pediatrics; Program in Molecular Medicine; Department of Medicine, Division of Diabetes; Department of Molecular Genetics and Microbiology
AIDS Vaccines; Adolescent; *Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cytokines; Female; Flow Cytometry; Fowlpox virus; Gene Products, gag; HIV Antibodies; HIV Infections; HIV-1; Humans; Interferon-gamma; Male; Prospective Studies; RNA, Viral; T-Lymphocytes; Vaccines, Synthetic; Vaccinia; Young Adult
Immunology and Infectious Disease | Pediatrics
A trial to evaluate the safety and immunogenicity of recombinant modified vaccinia Ankara (MVA) and fowlpox (FP) vectors expressing multiple HIV-1 proteins was conducted in twenty HIV-1 infected youth with suppressed viral replication on HAART. The MVA and FP-based multigene HIV-1 vaccines were safe and well tolerated. Increased frequencies of HIV-1 specific CD4+ proliferative responses and cytokine secreting cells were detected following immunization. Increased frequencies and breadth of HIV-1 specific CD8 T-cell responses were also detected. Plasma HIV-1-specific antibody levels and neutralizing activity were unchanged following vaccination. Poxvirus-based vaccines may merit further study in therapeutic vaccine protocols.
DOI of Published Version
Vaccine. 2008 Dec 9;26(52):6883-93. Epub 2008 Oct 20. Link to article on publisher's site
Greenough, Thomas C.; Cunningham, Coleen K.; Muresan, Petronella; McManus, Margaret M.; Persaud, Deborah; Fenton, Terry; Barker, Piers; Gaur, Aditya; Panicali, Dennis; Sullivan, John L.; and Luzuriaga, Katherine, "Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy" (2008). Immunology/Infectious Disease. 57.